OBJECTIVE: The purpose of this study was to examine the behavioral effects of four doses of psychostimulant medication, combining extended-release methylphenidate (MPH) in the morning with immediate-release MPH in the afternoon. METHOD: The sample comprised 24 children (19 boys; 5 girls) who met American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age=8.8 years, SD=1.7; mean intelligence quotient [IQ]=85; SD=16.8). Effects of four dose levels of MPH on parent and teacher behavioral ratings were investigated using a within-subject, crossover, placebo-controlled design. RESULTS: MPH treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school. Parents noted significant declines in inattentive and oppositional behavior, and improvements in social skills. No exacerbation of stereotypies was noted, and side effects were similar to those seen in typically developing children with ADHD. Dose response was primarily linear in the dose range studied. CONCLUSIONS: The results of this study suggest that MPH formulations are efficacious and well-tolerated for children with ASD and significant ADHD symptoms.
RCT Entities:
OBJECTIVE: The purpose of this study was to examine the behavioral effects of four doses of psychostimulant medication, combining extended-release methylphenidate (MPH) in the morning with immediate-release MPH in the afternoon. METHOD: The sample comprised 24 children (19 boys; 5 girls) who met American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age=8.8 years, SD=1.7; mean intelligence quotient [IQ]=85; SD=16.8). Effects of four dose levels of MPH on parent and teacher behavioral ratings were investigated using a within-subject, crossover, placebo-controlled design. RESULTS: MPH treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school. Parents noted significant declines in inattentive and oppositional behavior, and improvements in social skills. No exacerbation of stereotypies was noted, and side effects were similar to those seen in typically developing children with ADHD. Dose response was primarily linear in the dose range studied. CONCLUSIONS: The results of this study suggest that MPH formulations are efficacious and well-tolerated for children with ASD and significant ADHD symptoms.
Authors: Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel Journal: J Child Adolesc Psychopharmacol Date: 2011-12-13 Impact factor: 2.576
Authors: David J Posey; Michael G Aman; James T McCracken; Lawrence Scahill; Elaine Tierney; L Eugene Arnold; Benedetto Vitiello; Shirley Z Chuang; Mark Davies; Yaser Ramadan; Andrea N Witwer; Naomi B Swiezy; Pegeen Cronin; Bhavik Shah; Deirdre H Carroll; Christopher Young; Courtney Wheeler; Christopher J McDougle Journal: Biol Psychiatry Date: 2007-02-15 Impact factor: 13.382
Authors: Ovsanna T Leyfer; Susan E Folstein; Susan Bacalman; Naomi O Davis; Elena Dinh; Jubel Morgan; Helen Tager-Flusberg; Janet E Lainhart Journal: J Autism Dev Disord Date: 2006-10
Authors: James M Swanson; Sabrina Schuck; Miranda Mann Porter; Caryn Carlson; Catharina A Hartman; Joseph A Sergeant; Walter Clevenger; Michael Wasdell; Richard McCleary; Kimberley Lakes; Timothy Wigal Journal: Int J Educ Psychol Assess Date: 2012-04
Authors: Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; David M Lane; Katherine A Loveland; Rosleen Mansour; Anthony R Ward; Charles D Casat; Susan Jerger; Russell J Schachar; Oscar G Bukstein; Lynne A Cleveland Journal: J Child Adolesc Psychopharmacol Date: 2020-07-09 Impact factor: 2.576
Authors: Katharine C Reynolds; Michelle Patriquin; Candice A Alfano; Katherine A Loveland; Deborah A Pearson Journal: Res Autism Spectr Disord Date: 2017-05-03
Authors: Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle Journal: Neuropsychopharmacology Date: 2018-02-27 Impact factor: 7.853
Authors: Xinyue Liu; Paul R Carney; Regina Bussing; Richard Segal; Linda B Cottler; Almut G Winterstein Journal: J Child Adolesc Psychopharmacol Date: 2017-10-13 Impact factor: 2.576
Authors: Rosleen Mansour; Anthony R Ward; David M Lane; Katherine A Loveland; Michael G Aman; Susan Jerger; Russell J Schachar; Deborah A Pearson Journal: Res Dev Disabil Date: 2021-02-03
Authors: Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2015-11-25